Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis

Area of Science:

• Neuroimmunology
• Cellular Therapy
• Clinical Trials

Background:

• Progressive multiple sclerosis (PMS) involves relentless central nervous system (CNS) inflammation driven by B cells.
• Current B cell therapies struggle to target plasma cells within the CNS, limiting efficacy in PMS.

Purpose of the Study:

• To evaluate the safety and efficacy of anti-BCMA CAR-T cell therapy in patients with PMS.
• To investigate the impact of anti-BCMA CAR-T cell therapy on CNS B cells and inflammation.

Main Methods:

• A phase 1 clinical trial involving five patients with PMS treated with anti-BCMA CAR-T cells.
• Monitoring for adverse events, including cytokine release syndrome and cytopenias.
• Assessing CAR-T cell activity, plasma cell depletion in CNS compartments, and microglial activation via cerebrospinal fluid analysis.

Main Results:

• Anti-BCMA CAR-T cell therapy was generally well-tolerated, with only grade 1 cytokine release syndrome observed.
• Transient grade ≥3 cytopenias occurred within 40 days post-infusion.
• Therapy led to plasma cell depletion in CNS compartments, sustained CAR-T cell activity in cerebrospinal fluid, and reduced microglial activation.

Conclusions:

• Anti-BCMA CAR-T cell therapy demonstrates potential for targeting CNS B cells in PMS.
• This approach may offer a novel therapeutic strategy for managing progressive multiple sclerosis.
• Further investigation is warranted to confirm the long-term efficacy and safety of this treatment.